Objective:

To explore the role of microbiota in the pathogenesis of systemic lupus erythematosus (SLE) and its implications for diagnosis and treatment, emphasizing its significance.

Key Findings:

• SLE is associated with significant dysbiosis across multiple body sites, which may exacerbate disease symptoms.
• Microbial alterations are linked to immune dysregulation and disease severity, indicating a need for targeted therapies.
• Microbiome-targeted therapies show promise in modulating immune responses, potentially leading to improved patient outcomes.

Interpretation:

The findings suggest that microbiota play a crucial role in SLE pathogenesis, highlighting the potential for microbiome-based therapies to enhance treatment outcomes and suggesting avenues for clinical application.

Limitations:

• Impact of immunosuppressants on microbiota is not fully understood, which may affect treatment strategies.
• Spatial heterogeneity in host-microbe interactions complicates causal inference, necessitating more nuanced research.
• Current studies may lack long-term follow-up data, limiting the understanding of microbiome interventions' durability.

Conclusion:

Reframing SLE as a 'meta-organismal imbalance' emphasizes the importance of microbial ecology in precision medicine and suggests a shift towards personalized microbiome-based therapies, with practical implications for treatment.